Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income
countries.On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novavax becomes fifth COVID-19 vaccine developer to release promising early resultsThe candidate vaccine seems to have generated an immune reaction similar to those in people who have recovered from COVID-19, the data shows.
Weiterlesen »
Novavax becomes fifth COVID-19 vaccine developer to release promising early results'Good news,' said Dr. William Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine. 'I think it clearly boosts confidence that we will have one or more vaccines.'
Weiterlesen »
Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccinesCanada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.
Weiterlesen »
An Alabama high school principal turned 'U Can't Touch This' into Covid-19 safety videoIn a video for his students that went viral, an Alabama educator channeled his background in music to help his school prepare for reopening in the era of Covid-19.
Weiterlesen »